Koru Medical price target lowered to $3.50 from $4.50 at Piper Sandler

Piper Sandler analyst Jason Bednar lowered the firm’s price target on Koru Medical (KRMD) to $3.50 from $4.50 and keeps a Neutral rating on the shares. The firm notes the company reported Q1 results that beat Street, including revenue of $9.6M/+17.5% year-over-year as U.S./International grew 16%/36%, respectively. The beat was wide enough for management to bump 2025 revenue guidance higher by $0.5M, Piper says, adding that it’s encouraging to see gross margin percentage durability despite the geographic mix shift, and management also highlighted plans to submit for approval later this year for two commercialized drugs on the company’s Freedom Infusion System.